FDA imposes strongest warnings against off-label obstetric use of terbutaline
This article was originally published in Scrip
Executive Summary
The US FDA 17 February imposed a black-box warning on the labelling of the asthma drug terbutaline alerting doctors not to use the medicine in pregnant women to prevent preterm labour, an unapproved indication.